Horizon Pharma (HZNP) Management Lunch Offers Upbeat Outlook - Stifel

Stifel analyst Annabel Samimy reiterated a Buy rating and $35.00 price target on Horizon Pharma (NASDAQ: HZNP) after hosting an upbeat lunch with CEO Tim Walbert. The meeting was upbeat as Krystexxa/chronic refractory gout and teprotumumab/TED offer a line of sight to revenue growth for the foreseeable future.

The analyst stated "we continue to see double digit volume growth for Krystexxa and see multiple avenues for upside to peak, namely increased vial usage and label expansion in kidney transplant patients. Teprotumumab is rapidly headed to market, with BLA acceptance and Priority Review (PDUFA 3/8/19, launch 1Q20). With its sales force in place, HZNP has gained a strong handle on how to approach the market and should be well-prepared for solid execution of this disease-modifying product. We continue to view HZNP shares on the precipice of finally reflecting its BioPharma profile".

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $26.43 yesterday.

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• Weatherford International plc (WFRD) PT Raised to $184 at Piper Sandler
• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies